[ RECIPIENT ENTITY RECORD ]

Icosavax

VERIFIED NODE ID: 001729 · icosavax
R TARGET NODE — CAPITAL RECIPIENT
Icosavax
Company United States
Recipient Type
Company
Primary Jurisdiction
United States
Registration Status
ACTIVE
Entity Intelligence [ R ]
Legal Name Icosavax
Entity Type Company
Jurisdiction United States
Recipient Intelligence Summary

Icosavax is a biopharmaceutical company that utilizes a virus-like particle platform to develop vaccines for infectious diseases, particularly respiratory viruses. Based in Washington, the company focuses on vaccines for the elderly and vulnerable populations. It was a significant destination for institutional healthcare capital through a strategic biotech acquisition.

Capital Influx Log (Transactions)
Date Type Amount
22 May 2026 EQUITY $1.1B